MX9304638A - Composicion para tratar e inhibir las ulceras gastricas y duodenales. - Google Patents

Composicion para tratar e inhibir las ulceras gastricas y duodenales.

Info

Publication number
MX9304638A
MX9304638A MX9304638A MX9304638A MX9304638A MX 9304638 A MX9304638 A MX 9304638A MX 9304638 A MX9304638 A MX 9304638A MX 9304638 A MX9304638 A MX 9304638A MX 9304638 A MX9304638 A MX 9304638A
Authority
MX
Mexico
Prior art keywords
duodenal ulcers
treat
composition
inhibit gastric
gastric
Prior art date
Application number
MX9304638A
Other languages
English (en)
Inventor
Stephen Roth
Edward J Mcguire
Dennis H Langer
Original Assignee
Neose Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neose Pharm Inc filed Critical Neose Pharm Inc
Publication of MX9304638A publication Critical patent/MX9304638A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a compuestos y composiciones de oligosicaridos para tratar e inhibir las úlceras gástricas u duodenales, y a métodos para tratar e inhibir las ulceras gástricas y duodenales.
MX9304638A 1992-07-31 1993-07-30 Composicion para tratar e inhibir las ulceras gastricas y duodenales. MX9304638A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92251992A 1992-07-31 1992-07-31
US10448393A 1993-07-28 1993-07-28

Publications (1)

Publication Number Publication Date
MX9304638A true MX9304638A (es) 1994-05-31

Family

ID=26801599

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9304638A MX9304638A (es) 1992-07-31 1993-07-30 Composicion para tratar e inhibir las ulceras gastricas y duodenales.

Country Status (3)

Country Link
US (4) US5620964A (es)
CN (1) CN1078074C (es)
MX (1) MX9304638A (es)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
US5834002A (en) * 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
EP0795560B1 (en) * 1994-12-01 2003-12-10 Seikagaku Corporation Keratan sulfate oligosaccharide fraction and drug containing the same
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
WO1997041875A1 (en) * 1996-05-03 1997-11-13 Neose Technologies, Inc. Bismuth salt of sialyloligosaccharide and a method for treating and inhibiting gastric and duodenal ulcers with same
WO1997047646A1 (en) * 1996-06-10 1997-12-18 Boren Thomas Helicobacter pylori adhesin binding group antigen
CA2261877C (en) * 1996-07-23 2009-04-07 Seikagaku Corporation Novel lactosamine oligosaccharide and method for producing the same
AU6584298A (en) * 1997-03-26 1998-10-20 Avant Immunotherapeutics, Inc. Carbohydrate antigens which immunoreact with polyclonal antisera against (h. pylori)
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
EP0980204A4 (en) * 1997-04-01 2005-06-15 Merieux Oravax 76 kDa, 32 kDa and 50 kDa HELICOBACTER POLYPEPTIDES AND CORRESPONDING POLYNUCLEOTIDE MOLECULES
US20030124141A1 (en) * 1997-04-01 2003-07-03 Rainer Haas Helicobacter polypeptides and corresponding polynucleotide molecules
WO1998048817A1 (en) * 1997-05-01 1998-11-05 Cytel Corporation Use of sialyl galactosides and related compounds as anti-angiogenic agents
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6323008B1 (en) * 1997-08-14 2001-11-27 Neose Technologies, Inc. Methods for producing sialyloligosaccharides in a dairy source
US6013680A (en) * 1997-10-21 2000-01-11 Amano Pharmaceutical Co., Ltd. Digestive enzyme-containing medicament
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
WO1999057300A1 (en) 1998-05-05 1999-11-11 Mcneil Specialty Products Company Division Of Mcneil-Ppc, Inc. Functional sugar polymers from inexpensive sugar sources and apparatus for preparing same
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
KR100460173B1 (ko) * 1998-12-11 2004-12-04 겐 코오포레이션 헬리코박터 파일로리 정착 억제제
AU6557299A (en) 1999-01-07 2000-07-13 Seikagaku Corporation Method for producing oligosaccharide, and novel oligosaccharide and pharaceutical composition containing the same
EP1074260B1 (en) 1999-07-21 2004-02-18 Seikagaku Corporation IL-12 Production inhibitor
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
AUPQ275799A0 (en) * 1999-09-10 1999-10-07 Luminis Pty Limited Recombinant bacterium expressing an oligosaccharide receptor mimic
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
ATE357854T1 (de) * 2000-02-17 2007-04-15 Wyeth Corp Prebiotische substanzen enthaltende ernährungszusammensetzungen
US6630452B2 (en) 2000-02-17 2003-10-07 Wyeth Nutritional formulation containing prebiotic substances
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20020197314A1 (en) 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
FI20011403L (fi) * 2001-06-29 2002-12-30 Carbion Oy Menetelmä ja koostumukset vatsan sairauksien hoitoon
WO2003002127A1 (en) * 2001-06-29 2003-01-09 Glykos Finland Oy Use of at least one glycoinhibitor substance
US20040241689A1 (en) * 2001-07-31 2004-12-02 Baseman Joel B. Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
US6946451B2 (en) 2002-02-04 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Insulin secretion promoter
ATE428430T1 (de) * 2002-06-28 2009-05-15 Glykos Finland Oy Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
BR0315209A (pt) * 2002-10-11 2005-08-16 Wyeth Corp Formulações nutritivas que contêm substâncias simbióticas
FI20021989A0 (fi) * 2002-11-06 2002-11-06 Halina Miller-Podraza Korkean affiniteetin Helicobacter pylori-reseptorit ja niiden käyttö
US20040114368A1 (en) * 2002-12-13 2004-06-17 Shyu Shing Jy Light device having rotatable or movable view
US7238677B2 (en) * 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) * 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
US8460710B2 (en) * 2003-09-15 2013-06-11 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050095219A1 (en) * 2003-10-29 2005-05-05 Shu-Ping Yang Compositions for promoting vaginal cell proliferation and maturation
WO2005062898A2 (en) * 2003-12-24 2005-07-14 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
US20050234448A1 (en) * 2004-03-19 2005-10-20 Mccarthy James Implantable bone-lengthening device
JP2008505124A (ja) * 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2009105568A1 (en) 2008-02-20 2009-08-27 The Curators Of The University Of Missouri Composition comprising a combination of omeprazole and lansoprazole, and a buffering agent, and methods of using same
RU2410100C2 (ru) * 2009-03-30 2011-01-27 Александр Владимирович Диковский Фармацевтическая композиция ингибитора протонной помпы и пребиотика для лечения язвенных поражений желудка и 12-перстной кишки
IT1394503B1 (it) * 2009-04-06 2012-07-05 Inalco Spa Sali di 6'-sialillattosio e processo per la loro sintesi e per la sintesi di altri alfa-sialiloligosaccaridi.
US9578895B2 (en) 2010-08-23 2017-02-28 Epc (Beijing) Natural Products Co., Ltd. Rebaudioside A and stevioside compositions
MY165628A (en) 2010-12-31 2018-04-18 Abbott Lab Human milk oligosaccharides for modulating inflammation
US9795156B2 (en) 2011-03-17 2017-10-24 E.P.C (Beijing) Plant Pharmaceutical Technology Co., Ltd Rebaudioside B and derivatives
NL2007931C2 (en) 2011-12-07 2013-06-10 Friesland Brands Bv Methods for providing sialylated oligosaccharides and products obtainable thereby.
WO2025088057A1 (en) * 2023-10-24 2025-05-01 Dsm Ip Assets B.V. Use of 2'-fucosyllactose or 3'-sialyllactose for reducing the growth of microbes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4762822A (en) * 1985-08-08 1988-08-09 Ettinger Anna C Reduction of gastrointestinal disease-producing organisms with sialic acid and gangliosides
EP0265061B1 (en) * 1986-09-18 1992-01-08 London School of Pharmacy Innovations Ltd Pharmaceutical formulation
SE464687B (sv) * 1987-11-10 1991-06-03 Biocarb Ab Foerfarande foer framstaellning av en gelprodukt
EP0357793B1 (en) * 1988-03-09 1994-05-25 Snow Brand Milk Products Co., Ltd. Suspended-release preparation prepared by using alginates
US4935406A (en) * 1988-09-20 1990-06-19 Marion Laboratories, Inc. Use of bismuth (phosph/sulf)ated saccharides against Camplyobacter-associated gastrointestinal disorders
US5089479A (en) * 1988-11-28 1992-02-18 Krivan Howard C Adhesion of mycoplasma pneumoniae and mycoplasma hominus to sulfatide
US5348869A (en) * 1988-08-02 1994-09-20 Hoffmann-La Roche Inc. Process for producing tocopherols with spheroplasts of algae
US5260280A (en) * 1989-02-07 1993-11-09 Snow Brand Milk Products Co., Ltd. Bacterial toxin neutralizer
US5211937A (en) * 1990-07-30 1993-05-18 Glycomed Incorporated Method of determining a site of inflammation utilizing elam-1 ligands
US5300302A (en) * 1990-10-04 1994-04-05 Nestec S.A. Pharmaceutical composition in gel form in a dispensing package
US5164374A (en) * 1990-12-17 1992-11-17 Monsanto Company Use of oligosaccharides for treatment of arthritis
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5254676A (en) * 1991-11-22 1993-10-19 E. I. Du Pont De Nemours And Company Oligosaccharide inhibitors for influenza virus
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.

Also Published As

Publication number Publication date
US5514660A (en) 1996-05-07
US5883079A (en) 1999-03-16
CN1085430A (zh) 1994-04-20
US5620964A (en) 1997-04-15
US5753630A (en) 1998-05-19
CN1078074C (zh) 2002-01-23

Similar Documents

Publication Publication Date Title
MX9304638A (es) Composicion para tratar e inhibir las ulceras gastricas y duodenales.
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DK0480077T3 (da) Fremgangsmåde til fremstilling af carnosinsyre
DE69213231D1 (de) Zusammensetzung und methode zur verstärkung der sonnenbräunung
ES2135083T3 (es) Trifeniletilenos para la prevencion y el tratamiento de la osteoporosis.
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DK0840732T3 (da) Substituerede benzolactamforbindelser som substans P-antagonister
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
DK0981341T3 (da) Anvendelse af betulinsyrederivater til behandling og forebyggelse af melanom
NO996578L (no) Urokinase-inhibitorer
AP9200410A0 (en) Retroviral protease inhibitors.
ATE227293T1 (de) 2,3-disubstituierte-(5,6)-heteroarylkondensiert - pyrimidin-4-one
DK0701546T3 (da) Aromatiske acetylchlolinesteraseinhibitorer
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
SI1000034T1 (en) Substituted 6-alkylphenanthridines
PL329413A1 (en) Chemical compounds exhibiting properties capable to cause growth hormone release
AU4993893A (en) Compositions for treating and inhibiting gastric and duodenal ulcers
DE69301904D1 (de) Zusammensetzung zur behandlung von keratinfasern
DE68911776D1 (de) Konjugierte Oxybutenolide zur Behandlung von Ulcera.
NO943765L (no) Aryloksybenzen-herbicidmidler
EP0612527A3 (en) Use of rhamnan, rhamnose or rhamnose oligomers for the treatment of gastric ulcer.
PT80152B (de) Methode zur behandlung des glaukoms vok
DE69429013D1 (de) Verwendung von dimeticon zur behandlung der konstipation
SE9200502D0 (sv) Novel antioxidants
DE68913995D1 (de) Zusammensetzung zur behandlung progressiver myopie.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees